---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-006281"
form_type: "8-K"
ticker: "SBFM"
cik: "0001402328"
company_name: "Sunshine Biopharma Inc."
filed_at: "2024-09-10T23:59:59+00:00"
generated_at: "2026-05-31T05:36:31.657118+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Sunshine Biopharma regains Nasdaq bid-price compliance; faces 1-year monitoring with strict delisting risk

## Summary
- Received Nasdaq letter confirming compliance with Bid Price Rule (Listing Rule 5550(a)(2)).
- Subject to Mandatory Panel Monitor for one year from September 9, 2024.
- If non-compliant during monitoring, no cure period allowed; Nasdaq will issue Delist Determination Letter.
- Company may request a new hearing if delist determination is issued.

## SEC filing metadata
- accession: 0001683168-24-006281
- form_type: 8-K
- ticker: SBFM
- cik: 0001402328
- company_name: Sunshine Biopharma Inc.
- filed_at: 2024-09-10T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1402328/000168316824006281/0001683168-24-006281-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1402328/000168316824006281/sunshine_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-006281
- JSON: https://secwatch.observer/filing/0001683168-24-006281.json
- Plain text: https://secwatch.observer/filing/0001683168-24-006281.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.